What is the 13F Pro Quality Score for RLYB?

13F Pro ranks Rallybio Corp (RLYB) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RLYB's current score at https://13fpro.ai/research/RLYB (free sign-up required for the full ranking).

Which hedge funds own the most RLYB stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of RLYB include FMR, VIKING GLOBAL INVESTORS, Cormorant Asset Management,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/RLYB as soon as new 13F filings post.

Where does 13F Pro source RLYB data?

All Rallybio Corp fundamentals and ownership data come directly from SEC EDGAR. Rallybio Corp files with the SEC under CIK 1739410. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RLYB in?

Rallybio Corp (RLYB) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is RLYB research updated on 13F Pro?

RLYB's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Rallybio Corp(RLYB)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1739410 RLYB stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.9M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

RLYB Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Rallybio Corp (RLYB), a Healthcare sector company. RLYB is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.9m in revenue. Based on the latest XBRL financial filings (Q1 2026), Rallybio Corp reports quarterly revenue of $212.0K, net income of $-8.3M, free cash flow of $-8.0M. Top institutional holders of RLYB by reported 13-F value include FMR, VIKING GLOBAL INVESTORS, Cormorant Asset Management,, based on the most recent SEC filings. RLYB trades on the Nasdaq exchange and files with the SEC under CIK 1739410. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RLYB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Rallybio Corp directly from SEC EDGAR.

Revenue

Q1 2026

$212.0K

Net Income

Q1 2026

$-8.3M

Free Cash Flow

Q1 2026

$-8.0M

ROIC

Q1 2026

-17.4%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+34.9% YoY

$858.0KFY 2025

FY22 —FY23 —FY24 $636.0KFY25 $858.0K

Net Income

+84.5% YoY

$-9.0MFY 2025

FY22 $-66.7MFY23 $-74.6MFY24 $-57.8MFY25 $-9.0M

Operating Income

+45.3% YoY

$-33.1MFY 2025

FY22 $-67.9MFY23 $-78.9MFY24 $-60.5MFY25 $-33.1M

EPS (Diluted)

+85.0% YoY

$-1.59FY 2025

FY22 $-2.09FY23 $-1.84FY24 $-10.61FY25 $-1.59

Total Assets

-8.6% YoY

$62.3MFY 2025

FY22 $180.4MFY23 $115.6MFY24 $68.1MFY25 $62.3M

Op. Cash Flow

+39.5% YoY

$-29.8MFY 2025

FY22 $-57.3MFY23 $-60.3MFY24 $-49.3MFY25 $-29.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$858.0K +34.9%	$636.0K	—	—	—	—
Net Income	$-9.0M +84.5%	$-57.8M +22.5%	$-74.6M -11.9%	$-66.7M -41.8%	$-47.0M -77.8%	$-26.4M
Operating Income	$-33.1M +45.3%	$-60.5M +23.4%	$-78.9M -16.3%	$-67.9M -48.7%	$-45.6M -80.4%	$-25.3M
EPS (Diluted)	$-1.59 +85.0%	$-10.61 -476.6%	$-1.84 +12.0%	$-2.09 -13.6%	$-1.84	—
Total Assets	$62.3M -8.6%	$68.1M -41.1%	$115.6M -35.9%	$180.4M -1.0%	$182.2M +28.4%	$141.9M
Operating Cash Flow	$-29.8M +39.5%	$-49.3M +18.2%	$-60.3M -5.2%	$-57.3M -25.8%	$-45.5M -106.6%	$-22.0M

AI Insight: RLYB Financial Trends

Pre-revenue biotech burning cash steadily while equity base erodes, with a mysterious $16M net income spike in Q3 2025 requiring clarification.

• Operating cash burn moderated to $5–8M per quarter in Q4 2025–Q1 2026, down from $10–14M in H2 2024.

• Equity base contracted 38% from $80M (Q2 2024) to $50M (Q1 2026) despite zero revenue; cumulative cash drain evident.

• Q3 2025 posted unexpected $16M net income while operating income remained negative at $-7M—source and sustainability unclear.

⚠ Q3 2025 $16M net income anomaly demands explanation; if non-recurring, cash burn resumes at $6–10M quarterly pace.

⚠ At current $8M quarterly burn rate, remaining $50M equity provides ~6 quarters of runway without revenue inflection.

AI Insight: RLYB Ratio Trends

Rallybio remains deeply unprofitable with no clear path to positive returns; Q3 2025's anomalous positive ROE masks persistent operational losses.

• ROE, ROA, and ROIC have remained negative across all periods, ranging from -15.6% to -87.5%, indicating consistent net losses and minimal asset productivity.

• Q3 2025 showed a sharp, isolated spike to ROE +101.6% and ROA +94.7%, but reverted to ROE -40.4% and ROA -37.6% in Q4 2025, suggesting a one-off event rather than operational improvement.

• TTM (trailing twelve months) metrics show modest improvement from Q2 2025 lows (ROE -84.4%, ROIC -87.5%) to TTM levels (ROE -15.6%, ROIC -63.9%), but remain significantly negative.

⚠ Q3 2025 anomaly requires investigation: a dramatic swing to positive returns followed by reversion suggests accounting or timing effects, not sustainable profitability.

⚠ No operating or net profit margin data available; inability to assess cost structure or pricing power limits visibility into path to profitability.

Get alerted when RLYB's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Rallybio Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RLYB

FMR LLC
$7.1M793,451 sh
VIKING GLOBAL INVESTORS LP
$4.7M524,347 sh
Cormorant Asset Management, LP
$3.6M400,000 sh
TPG GP A, LLC
$3.4M378,551 sh
BALYASNY ASSET MANAGEMENT L.P.
$3.4M376,573 sh
Laurion Capital Management LP
$2.7M302,756 sh
Nantahala Capital Management, LLC
$2.7M300,635 sh
Pivotal bioVenture Partners Investment Advisor LLC
$2.7M300,579 sh
5AM Venture Management, LLC
$2.6M291,788 sh
Almitas Capital LLC
$1.7M191,206 sh

Fund	Value	Shares
FMR LLC	$7.1M	793,451
VIKING GLOBAL INVESTORS LP	$4.7M	524,347
Cormorant Asset Management, LP	$3.6M	400,000
TPG GP A, LLC	$3.4M	378,551
BALYASNY ASSET MANAGEMENT L.P.	$3.4M	376,573
Laurion Capital Management LP	$2.7M	302,756
Nantahala Capital Management, LLC	$2.7M	300,635
Pivotal bioVenture Partners Investment Advisor LLC	$2.7M	300,579
5AM Venture Management, LLC	$2.6M	291,788
Almitas Capital LLC	$1.7M	191,206

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put RLYB on your watchlist

Track score changes the day Rallybio Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RLYB a good stock to buy?

13F Pro's AI-powered analysis of Rallybio Corp (RLYB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RLYB are available on the RLYB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own RLYB?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RLYB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Rallybio Corp's investment landscape.